Paul A Fedalen, MD | |
540 S Governors Ave Ste 101a, Dover, DE 19904-3530 | |
(302) 744-7980 | |
(302) 744-7989 |
Full Name | Paul A Fedalen |
---|---|
Gender | Male |
Speciality | Cardiac Surgery |
Experience | 30 Years |
Location | 540 S Governors Ave Ste 101a, Dover, Delaware |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1538151741 | NPI | - | NPPES |
1000032899 | Medicaid | DE |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208G00000X | Thoracic Surgery (cardiothoracic Vascular Surgery) | C1-0007342 (Delaware) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Bayhealth Hospital, Kent Campus | Dover, DE | Hospital |
Bayhealth Hospital, Sussex Campus | Milford, DE | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Bayhealth Medical Center, Inc | 1658364740 | 288 |
News Archive
This week marks a grim milestone: Half a million Americans have died of Covid-19. KHN reporter Jenny Gold, in collaboration with Reveal from the Center for Investigative Reporting and PRX, spent eight months following one first-year medical resident working on the front lines of the pandemic.
People who undergo nonmyeloablative stem-cell transplants, or "mini transplants," for leukemia, lymphoma and other blood cancers have comparable outcomes regardless of whether they receive tissue-matched stem cells from a related or unrelated donor, according to new findings by researchers at Fred Hutchinson Cancer Research Center.
Sermo, the world's largest online community for physicians, today announced a Sermo Event™ Report titled "Evolving Trends in CML." The new report measures the impact of ENESTnd trial data on Oncologists' use of Tasigna (Novartis), Sprycel (Bristol Myers-Squibb) and Gleevec (Novartis) in newly diagnosed CML patients and assesses overall trends in CML monitoring and management. While Gleevec will likely remain the #1 treatment, there will be a close race for the runner-up spot amongst second-generation tyrosine kinase inhibitors in the front line setting.
Researchers from the Liverpool School of Tropical Medicine have shown the large potential impact of a completely new type of antimalarial drug that kills mosquitoes, as opposed to existing drugs that target the parasite, to reduce the spread of malaria.
Resistance to therapy is a major problem in cancer patients as the cells that resist to therapy is at the root of tumor relapse and is associated with high morbidity and mortality.
› Verified 7 days ago
Entity Name | Bayhealth Medical Center, Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1467546135 PECOS PAC ID: 1658364740 Enrollment ID: O20040405001600 |
News Archive
This week marks a grim milestone: Half a million Americans have died of Covid-19. KHN reporter Jenny Gold, in collaboration with Reveal from the Center for Investigative Reporting and PRX, spent eight months following one first-year medical resident working on the front lines of the pandemic.
People who undergo nonmyeloablative stem-cell transplants, or "mini transplants," for leukemia, lymphoma and other blood cancers have comparable outcomes regardless of whether they receive tissue-matched stem cells from a related or unrelated donor, according to new findings by researchers at Fred Hutchinson Cancer Research Center.
Sermo, the world's largest online community for physicians, today announced a Sermo Event™ Report titled "Evolving Trends in CML." The new report measures the impact of ENESTnd trial data on Oncologists' use of Tasigna (Novartis), Sprycel (Bristol Myers-Squibb) and Gleevec (Novartis) in newly diagnosed CML patients and assesses overall trends in CML monitoring and management. While Gleevec will likely remain the #1 treatment, there will be a close race for the runner-up spot amongst second-generation tyrosine kinase inhibitors in the front line setting.
Researchers from the Liverpool School of Tropical Medicine have shown the large potential impact of a completely new type of antimalarial drug that kills mosquitoes, as opposed to existing drugs that target the parasite, to reduce the spread of malaria.
Resistance to therapy is a major problem in cancer patients as the cells that resist to therapy is at the root of tumor relapse and is associated with high morbidity and mortality.
› Verified 7 days ago
Entity Name | Bayhealth Medical Center, Inc |
---|---|
Entity Type | Part B Supplier - Hospital Department(s) |
Entity Identifiers | NPI Number: 1023006434 PECOS PAC ID: 1658364740 Enrollment ID: O20160527000094 |
News Archive
This week marks a grim milestone: Half a million Americans have died of Covid-19. KHN reporter Jenny Gold, in collaboration with Reveal from the Center for Investigative Reporting and PRX, spent eight months following one first-year medical resident working on the front lines of the pandemic.
People who undergo nonmyeloablative stem-cell transplants, or "mini transplants," for leukemia, lymphoma and other blood cancers have comparable outcomes regardless of whether they receive tissue-matched stem cells from a related or unrelated donor, according to new findings by researchers at Fred Hutchinson Cancer Research Center.
Sermo, the world's largest online community for physicians, today announced a Sermo Event™ Report titled "Evolving Trends in CML." The new report measures the impact of ENESTnd trial data on Oncologists' use of Tasigna (Novartis), Sprycel (Bristol Myers-Squibb) and Gleevec (Novartis) in newly diagnosed CML patients and assesses overall trends in CML monitoring and management. While Gleevec will likely remain the #1 treatment, there will be a close race for the runner-up spot amongst second-generation tyrosine kinase inhibitors in the front line setting.
Researchers from the Liverpool School of Tropical Medicine have shown the large potential impact of a completely new type of antimalarial drug that kills mosquitoes, as opposed to existing drugs that target the parasite, to reduce the spread of malaria.
Resistance to therapy is a major problem in cancer patients as the cells that resist to therapy is at the root of tumor relapse and is associated with high morbidity and mortality.
› Verified 7 days ago
Mailing Address | Practice Location Address |
---|---|
Paul A Fedalen, MD 640 S. State Street, Mail Code 3055, Dover, DE 19901 Ph: (302) 480-1688 | Paul A Fedalen, MD 540 S Governors Ave Ste 101a, Dover, DE 19904-3530 Ph: (302) 744-7980 |
News Archive
This week marks a grim milestone: Half a million Americans have died of Covid-19. KHN reporter Jenny Gold, in collaboration with Reveal from the Center for Investigative Reporting and PRX, spent eight months following one first-year medical resident working on the front lines of the pandemic.
People who undergo nonmyeloablative stem-cell transplants, or "mini transplants," for leukemia, lymphoma and other blood cancers have comparable outcomes regardless of whether they receive tissue-matched stem cells from a related or unrelated donor, according to new findings by researchers at Fred Hutchinson Cancer Research Center.
Sermo, the world's largest online community for physicians, today announced a Sermo Event™ Report titled "Evolving Trends in CML." The new report measures the impact of ENESTnd trial data on Oncologists' use of Tasigna (Novartis), Sprycel (Bristol Myers-Squibb) and Gleevec (Novartis) in newly diagnosed CML patients and assesses overall trends in CML monitoring and management. While Gleevec will likely remain the #1 treatment, there will be a close race for the runner-up spot amongst second-generation tyrosine kinase inhibitors in the front line setting.
Researchers from the Liverpool School of Tropical Medicine have shown the large potential impact of a completely new type of antimalarial drug that kills mosquitoes, as opposed to existing drugs that target the parasite, to reduce the spread of malaria.
Resistance to therapy is a major problem in cancer patients as the cells that resist to therapy is at the root of tumor relapse and is associated with high morbidity and mortality.
› Verified 7 days ago
Gary Walter Szydlowski, MD Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 540 S Governors Ave Ste 101a, Dover, DE 19904 Phone: 302-744-7980 Fax: 302-744-7989 | |
Dr. Daniel Marelli, M.D. Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 540 S Governors Ave Ste 101a, Dover, DE 19904 Phone: 302-744-7980 Fax: 302-744-7989 | |
John Dana Mannion, M.D. Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Not Enrolled in Medicare Practice Location: 540 S Governors Ave, Suite 101a, Dover, DE 19904 Phone: 302-744-7980 |